Rallybio Corp RLYB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $15.69
- Day Range
- $15.51–15.85
- 52-Week Range
- $3.67–17.57
- Bid/Ask
- $15.42 / $15.88
- Shares Outstanding
- 5.38M
- Market Cap
- $84.80M
- Volume/Avg
- 59,284 / 18,171
Key Statistics
- Price/Earnings (Normalized)
- 12.93
- Price/Sales
- 209.12
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.rallybio.com
Valuation
Metric | RLYB |
|---|---|
Price/Earnings (Normalized) | 12.93 |
Price/Book Value | 0.91 |
Price/Sales | 209.12 |
Price/Cash Flow | 3.14 |
Price/Earnings
RLYB
Financial Strength
Metric | RLYB |
|---|---|
Quick Ratio | 27.63 |
Current Ratio | 28.87 |
Interest Coverage | — |
Quick Ratio
RLYB
Profitability
Metric | RLYB |
|---|---|
Return on Assets (Normalized) | −11.56% |
Return on Equity (Normalized) | −12.21% |
Return on Invested Capital (Normalized) | −14.74% |
Return on Assets
RLYB
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|HnpH<L | LOCK|%H^r | $139B | |||
| Moderna Inc MRNA | LOCK|$pldhy | LOCK|p@ | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|?hv<#? | LOCK|@y#R | $94B | |||
| argenx SE ADR ARGX | LOCK|ZKJHKFt | LOCK|&>S | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|#?>rSM | LOCK|^! | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&pch^X@Q | LOCK|<>jt | $30B | |||
| Incyte Corp INCY | LOCK|$^>btmS | LOCK|rs< | $24B | |||
| BioNTech SE ADR BNTX | LOCK|&J!H#lB | LOCK|%Z> | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|Y!&SZx | LOCK|!%GY | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|#>&Ldrr | LOCK|CSn | $15B |
United States